Zhi-Fu Tao

This inventor holds 45 USPTO granted patents and 50 published patent applications, plus 12 CIPO patents and 18 EPO patents, primarily in Cancer Therapeutics. Top assignees: Abbvie Inc., Abbott Laboratories Corporation, Walter and Eliza Hall Institute of Medical Research. Active years: 2007-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhi-Fu Tao. Retrieved from https://idiyas.com/inventor/zhi-fu-tao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 45 (Patent Applications = 50)

% Patents Active = 91.1

CIPO Patents = 12 (Patent Applications = 27)

EPO Patents = 18 (Patent Applications = 35)

Average Co-Inventor Count = 9.4

ph-index = 12

Forward Citations = 559(Granted Patents)

Location History:

Gunree, IL (US) (2013)
Vernon Hills, IL (US) (2014 - 2020)
Gurnee, IL (US) (2007 - 2024)

Company Filing History:

Abbott Laboratories Corporation

patents

5 out of 84

Walter and Eliza Hall Institute of Medical Research

where one patent can have more than one assignee

Years Active: 2007-2024

Loading Chart...

Areas of Expertise:

Apoptosis-Inducing Agents

MCL-1 Inhibitors

CDK9 Kinase Inhibitors

BCL-2 Selective Agents

Cancer Treatment

Immune Diseases

Autoimmune Diseases

Pyrrolo Compounds

Indole Derivatives

Heterocyclic Compounds

Macrocyclic Inhibitors

7-Substituted Indoles

45 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11897864 - Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases (2024-02-13),

2. 11786519 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2023-10-17),

3. 10676485 - Macrocyclic MCL-1 inhibitors and methods of use (2020-06-09),

4. 10081628 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2018-09-25),

5. 9877958 - Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases (2018-01-30),

6. 9844547 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2017-12-19),

7. 9796708 - Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors (2017-10-24),

8. 9650358 - Pyridine CDK9 kinase inhibitors (2017-05-16),

9. 9403822 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2016-08-02),

10. 9359296 - 7-substituted indole Mcl-1 inhibitors (2016-06-07),

11. 9346813 - Substituted pyrrolo[2,3-d]pyrimindines as CDK9 kinase inhibitors (2016-05-24),

12. 9315488 - Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases (2016-04-19),

13. 9303025 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2016-04-05),

14. 9266877 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2016-02-23),

15. 9227963 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases (2016-01-05),

Title: Inventor Zhi-Fu Tao: Pioneering Innovations in Gurnee

Introduction: Zhi-Fu Tao is a distinguished inventor based in Gurnee, Illinois, known for his groundbreaking contributions to various technological fields.

Latest Patents: Zhi-Fu Tao holds several patents in the areas of renewable energy, sustainable materials, and advanced electronics, showcasing his commitment to driving innovation forward.

Career Highlights: With a career spanning over two decades, Zhi-Fu Tao has worked with leading research institutions and companies to develop cutting-edge solutions that have had a significant impact on the industry.

Collaborations: Throughout his career, Zhi-Fu Tao has collaborated with top engineers, scientists, and researchers, fostering a culture of creativity and excellence in all his projects.

Conclusion: Zhi-Fu Tao's relentless pursuit of innovation and his passion for pushing the boundaries of technology make him a true visionary in the world of inventions.

Profile summary based on public USPTO records.